Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Relay Therapeutics Inc’s stock clocked out at $4.46, up 3.24% from its previous closing price of $4.32. In other words, the price has increased by $3.24 from its previous closing price. On the day, 3.39 million shares were traded. RLAY stock price reached its highest trading level at $4.59 during the session, while it also had its lowest trading level at $4.11.
Ratios:
To gain a deeper understanding of RLAY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.42 and its Current Ratio is at 18.42. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on September 10, 2024, Upgraded its rating to Buy and sets its target price to $16 from $10.60 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 03 ’25 when Rahmer Peter sold 32,177 shares for $4.30 per share. The transaction valued at 138,361 led to the insider holds 325,330 shares of the business.
Rahmer Peter sold 32,156 shares of RLAY for $133,447 on Jan 02 ’25. The insider now owns 357,507 shares after completing the transaction at $4.15 per share. On Jan 06 ’25, another insider, Rahmer Peter, who serves as the insider of the company, sold 16,576 shares for $4.45 each. As a result, the insider received 73,763 and left with 308,754 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 746528192 and an Enterprise Value of -43266008. For the stock, the TTM Price-to-Sale (P/S) ratio is 74.58 while its Price-to-Book (P/B) ratio in mrq is 0.89. Its current Enterprise Value per Revenue stands at -4.324 whereas that against EBITDA is 0.111.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.60, which has changed by -0.5636008 over the last 52 weeks, in comparison to a change of 0.23631513 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $11.16, while it has fallen to a 52-week low of $3.50. The 50-Day Moving Average of the stock is -6.50%, while the 200-Day Moving Average is calculated to be -30.86%.
Shares Statistics:
It appears that RLAY traded 2.20M shares on average per day over the past three months and 3700030 shares per day over the past ten days. A total of 166.89M shares are outstanding, with a floating share count of 123.45M. Insiders hold about 26.25% of the company’s shares, while institutions hold 73.19% stake in the company. Shares short for RLAY as of 1735603200 were 14952673 with a Short Ratio of 6.78, compared to 1732838400 on 11930533. Therefore, it implies a Short% of Shares Outstanding of 14952673 and a Short% of Float of 10.84.
